(Corrects date and day, and clarifies in 1st and 3rd paragraph different ways of administering vaccine)
(Reuters) – China’s CanSino Biologics Inc (CanSinoBIO) said on Tuesday it won approval for a clinical trial in the country to develop a COVID-19 vaccine for inhalation.
The National Medical Products Administration approved the trial of the vaccine, jointly developed by CanSinoBIO and the Beijing Institute of Biotechnology, the company said.
The company’s COVID-19 vaccine for injection was recently approved for emergency use in Hungary.
(This story corrects date and day, and clarifies in 1st and 3rd paragraph different ways of administering vaccine)
Source: Read Full Article